This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schrama, D. Articles by Becker, J. C. Search for Related Content PubMed PubMed Citation Articles by Schrama, D. Articles by Becker, J. C.

Oligoclonal T-Cell Receptor Usage of Melanocyte Differentiation Antigen-reactive T Cells in Stage IV Melanoma Patients¹

Department of Dermatology, Julius Maximilians-University, D-97080 Würzburg, Germany [D. S., P. T., J. C. B.], and Department of Tumor Cell Biology, Division of Cancer Biology, Danish Cancer Society, DK-2100 Copenhagen, Denmark [M. H. A., L. S., L. Ø. P., P. t. S., J. C. B.]

Ex vivo ELISPOT analysis of peripheral blood lymphocytes obtained from stage IV melanoma patients demonstrated reactivity against peptides derived from MART-1 and gp100. However, the number of reactive T cells was <1% that of total lymphocytes as detected by flow cytometry using tetrameric MHC/peptide complexes. Despite this low frequency, we were able to directly isolate these populations ex vivo by means of magnetic beads coated with MHC/peptide complexes and to subject these cells to T-cell receptor clonotype mapping. This analysis revealed that the MART-1/A*0201- and gp100/A*0201-reactive T-cell populations are composed of oligoclonal T cells that engage several T-cell receptor ß chain families. Longitudinal studies using this approach may result in a better correlation between T-cell reactivity and the course of neoplastic disease.

This article has been cited by other articles:

				L. Groneck, D. Schrama, M. Fabri, T. L. Stephen, F. Harms, S. Meemboor, H. Hafke, M. Bessler, J. C. Becker, and W. M. Kalka-Moll Oligoclonal CD4+ T Cells Promote Host Memory Immune Responses to Zwitterionic Polysaccharide of Streptococcus pneumoniae Infect. Immun., September 1, 2009; 77(9): 3705 - 3712. [Abstract] [Full Text] [PDF]

				R. Houben, H. Voigt, C. Noelke, V. Hofmeister, J. C. Becker, and D. Schrama MAPK-independent impairment of T-cell responses by the multikinase inhibitor sorafenib Mol. Cancer Ther., February 1, 2009; 8(2): 433 - 440. [Abstract] [Full Text] [PDF]

				M. H. Andersen, J. Fensterle, S. Ugurel, S. Reker, R. Houben, P. Guldberg, T. G. Berger, D. Schadendorf, U. Trefzer, E.-B. Brocker, et al. Immunogenicity of Constitutively Active V599EBRaf Cancer Res., August 1, 2004; 64(15): 5456 - 5460. [Abstract] [Full Text] [PDF]

				S. Mantovani, B. Palermo, S. Garbelli, R. Campanelli, G. Robustelli della Cuna, R. Gennari, F. Benvenuto, E. Lantelme, and C. Giachino Dominant TCR-{alpha} Requirements for a Self Antigen Recognition in Humans J. Immunol., December 1, 2002; 169(11): 6253 - 6260. [Abstract] [Full Text] [PDF]

				M. H. Andersen, L. O. Pedersen, B. Capeller, E.-B. Brocker, J. C. Becker, and P. thor Straten Spontaneous Cytotoxic T-Cell Responses against Survivin-derived MHC Class I-restricted T-Cell Epitopes in Situ As Well As ex Vivo in Cancer Patients Cancer Res., August 1, 2001; 61(16): 5964 - 5968. [Abstract] [Full Text] [PDF]